JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB87422

Goat Anti-Human IgG (Fab')2 (HRP)

Be the first to review this product! Submit a review

|

(12 Publications)

Goat Anti-Human IgG (Fab')2 (HRP) is a secondary antibody for chemiluminescent detection. Ideal for Western blot. Suitable for Western blot and ELISA.

- Reacts specifically with the Fab and F(ab')2 portion of human IgG
- Cited in over 5 publications

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1

1 Images
ELISA - Goat Anti-Human IgG (Fab')2 (HRP) (AB87422)
  • ELISA

PubMed

ELISA - Goat Anti-Human IgG (Fab')2 (HRP) (AB87422)

Characterisation of virus activity and functional expression of monoclonal antibodies.

(Panel D) IgG1 antibody expression, assessed by anti-IgG1 ELISA, in cellular supernatants of carcinoma cell lines infected for 24-96hrs with NG-135 at 1ppc.

Media was removed from infected or control cells, clarified by centrifugation and diluted 1 in 2 in 3% BSA/PBS for storage at -20°C. For quantification of human IgG1, 96 well plates were coated overnight, 4°C, with mouse monoclonal anti-human IgG1 Fc antibody (ab1927, Abcam) at a 1 : 1000 dilution in carbonate/bicarbonate buffer. Plates were blocked in 3% BSA/PBS, washed and samples and standards added to the plate for 1 hr and RT. Secondary detection was carried out using a HRP conjugated goat anti-human IgG Fab (ab87422, Abcam) incubated for 1 hr, RT.

Marino et al PLoS One. 2017 May 18;12(5):e0177810. doi: 10.1371/journal.pone.0177810. eCollection 2017. Fig 5. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

F(ab')2

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

HRP

Excitation/Emission
Applications

WB, ELISA

applications

Clonality

Polyclonal

Isotype

IgG

Specificity

ab87422 is specific for the Fab and F(ab')2 portion of human IgG by IEP. It reacts with other human immunoglobulins through common light chain reactivity.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/1000 - 1/10000", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/1000 - 1/10000", "notes":"<p></p>" } } }

Product details

This antibody reacts with the (Fab')2 region of Human IgG

When it comes to advancing your immunohistochemistry (IHC) research, Abcam offers comprehensive suite of IHC kits and secondary antibodies, designed to deliver precise and reliable results.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
This antibody has been cross adsorbed against the Fc domain and will react with less than 1 % of the Fc domain of human IgG.
Storage buffer
Preservative: 0.01% Thimerosal (merthiolate) Constituents: PBS, 0.1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.
See full target information IGHG1

Additional targets

IGHG2,IGHG3,IGHG4

Publications (12)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 16:1644391 PubMed41041320

2025

Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Rosa Rapuano Lembo,Margherita Passariello,Lorenzo Manna,Guendalina Froechlich,Martina Belardo,Alfredo Nicosia,Emanuele Sasso,Claudia De Lorenzo

Journal of cancer research and clinical oncology 151:184 PubMed40473914

2025

Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody.

Applications

Unspecified application

Species

Unspecified reactive species

Yuki Majima,David Kryza,Mitsuaki Sanada,Jacqueline Sidi-Boumedine,Patrick Mehlen,Benjamin Gibert,Jean-Yves Blay,Fumiyoshi Okano

Cell death discovery 11:58 PubMed39929828

2025

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Applications

Unspecified application

Species

Unspecified reactive species

Margherita Passariello,Lorenzo Manna,Rosa Rapuano Lembo,Asami Yoshioka,Toshikazu Inoue,Kentaro Kajiwara,Shu-Ichi Hashimoto,Koji Nakamura,Claudia De Lorenzo

Cell reports. Medicine 5:101483 PubMed38579727

2024

Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells.

Applications

Unspecified application

Species

Unspecified reactive species

Manuel Albanese,Hong-Ru Chen,Madeleine Gapp,Maximilian Muenchhoff,Hsiu-Hui Yang,David Peterhoff,Katja Hoffmann,Qianhao Xiao,Adrian Ruhle,Ina Ambiel,Stephanie Schneider,Ernesto Mejías-Pérez,Marcel Stern,Paul R Wratil,Katharina Hofmann,Laura Amann,Linda Jocham,Thimo Fuchs,Alessandro F Ulivi,Simon Besson-Girard,Simon Weidlich,Jochen Schneider,Christoph D Spinner,Kathrin Sutter,Ulf Dittmer,Andreas Humpe,Philipp Baumeister,Andreas Wieser,Simon Rothenfusser,Johannes Bogner,Julia Roider,Percy Knolle,Hartmut Hengel,Ralf Wagner,Vibor Laketa,Oliver T Fackler,Oliver T Keppler

mAbs 15:2281763 PubMed38031350

2023

Anti-citrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases.

Applications

Unspecified application

Species

Unspecified reactive species

Maarten van der Linden,Sangeeta Kumari,Daphne Montizaan,Stephanie van Dalen,Annemarie Kip,Martyn Foster,Inge Reinieren-Beeren,Elsa Neubert,Luise Erpenbeck,Kelsy Waaijenberg,Tirza Bruurmijn,Rezie Te Poele,Peter van Zandvoort,Paul Vink,Eric Meldrum,Helmuth van Es,Renato G S Chirivi

Life sciences 320:121525 PubMed36841470

2023

Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment.

Applications

Unspecified application

Species

Unspecified reactive species

Yahya Ehteshaminia,Seyedeh Farzaneh Jalali,Farhad Jadidi-Niaragh,Seyed Ehsan Enderami,Abdol Sattar Pagheh,Esmaeil Akbari,Saeid Abedian Kenari,Hadi Hassannia

NPJ vaccines 7:169 PubMed36535987

2022

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern.

Applications

Unspecified application

Species

Unspecified reactive species

Juan Shi,Gang Wang,Jian Zheng,Abhishek K Verma,Xiaoqing Guan,Moffat M Malisheni,Qibin Geng,Fang Li,Stanley Perlman,Lanying Du

Translational oncology 21:101424 PubMed35477065

2022

A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells.

Applications

Unspecified application

Species

Unspecified reactive species

Yumei Li,Lingjun Wu,Yueying Liu,Siwen Ma,Biyi Huang,Xianjing Feng,Hui Wang

mAbs 12:1684749 PubMed31775561

2019

Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences.

Applications

Unspecified application

Species

Unspecified reactive species

Gargi Roy,Jason Reier,Andrew Garcia,Tom Martin,Megan Rice,Jihong Wang,Meagan Prophet,Ronald Christie,William Dall'Acqua,Sanjeev Ahuja,Michael A Bowen,Marcello Marelli

mAbs 10:1060-1072 PubMed29995563

2018

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Emanuele Sasso,Chiara D'Avino,Margherita Passariello,Anna Morena D'Alise,Daniela Siciliano,Maria Luisa Esposito,Guendalina Froechlich,Riccardo Cortese,Elisa Scarselli,Nicola Zambrano,Alfredo Nicosia,Claudia De Lorenzo
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com